Tempus AI shares pulled back Friday after a five-day rally of nearly 40% driven by CEO Eric Lefkofsky's reimbursement projections at the ...

The U.S. is drafting rules for biopharma firms investing in China that would likely maintain their ability to ink most licensing deals for Chinese drugs. Read more here.

Companies are responding to patent cliffs and the increased cost of research and development for more complex products.

GSK slides 1.82% today to GBX1865.50 despite ongoing progress in oncology and vaccines, with volatility remaining elevated.

Pre-market movers are the stocks making the biggest moves before the 9:30 AM ET opening bell — pre-market trading runs from 4:00 AM ET. Because volumes are thinner than in the regular session, ...